The Manufacturers Life Insurance Company Sells 25,367 Shares of Agilent Technologies, Inc. (NYSE:A)

The Manufacturers Life Insurance Company cut its stake in shares of Agilent Technologies, Inc. (NYSE:AFree Report) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,399 shares of the medical research company’s stock after selling 25,367 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.10% of Agilent Technologies worth $38,706,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Jones Financial Companies Lllp bought a new position in Agilent Technologies in the fourth quarter worth approximately $49,000. APG Asset Management US Inc. acquired a new stake in Agilent Technologies in the 4th quarter valued at $7,836,000. California State Teachers Retirement System increased its stake in Agilent Technologies by 1.0% during the 4th quarter. California State Teachers Retirement System now owns 469,486 shares of the medical research company’s stock valued at $65,273,000 after purchasing an additional 4,788 shares in the last quarter. Lloyd Advisory Services LLC. acquired a new position in Agilent Technologies during the fourth quarter worth $205,000. Finally, Meritage Group LP lifted its stake in shares of Agilent Technologies by 28.3% in the fourth quarter. Meritage Group LP now owns 2,116,862 shares of the medical research company’s stock valued at $294,307,000 after buying an additional 467,451 shares in the last quarter.

Agilent Technologies Trading Down 0.5 %

Shares of A stock opened at $132.87 on Friday. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34. The firm has a market cap of $38.77 billion, a P/E ratio of 31.41, a PEG ratio of 4.44 and a beta of 1.07. The company has a 50 day moving average of $142.36 and a 200-day moving average of $137.67. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $155.35.

Agilent Technologies (NYSE:AGet Free Report) last released its earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same period last year, the business posted $1.27 earnings per share. The business’s revenue for the quarter was down 8.4% on a year-over-year basis. Sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.25 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd will be issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a yield of 0.71%. The ex-dividend date is Tuesday, July 2nd. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.22%.

Insiders Place Their Bets

In related news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares in the company, valued at approximately $3,274,050. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the sale, the chief executive officer now owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Philip Binns sold 2,827 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the transaction, the senior vice president now owns 9,997 shares of the company’s stock, valued at approximately $1,474,957.38. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on A. Citigroup lowered their target price on shares of Agilent Technologies from $145.00 to $135.00 and set a “neutral” rating on the stock in a report on Thursday, May 30th. Robert W. Baird lowered their price objective on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research note on Thursday, May 30th. UBS Group cut their target price on Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. Bank of America reissued a “neutral” rating and issued a $134.00 price target (down from $145.00) on shares of Agilent Technologies in a research report on Thursday, May 30th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $135.00 price objective (down from $152.00) on shares of Agilent Technologies in a report on Monday. One research analyst has rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $136.50.

View Our Latest Analysis on A

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.